Angiotensin II in inflammation, immunity and rheumatoid arthritis

Clinical and Experimental Immunology

Volumn 179, Issue 2, 2015, Pages 137-145

  Chang, Y ^a   Wei, W ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II; Immunity; Inflammation; Rheumatoid arthritis

Indexed keywords

ANGIOTENSIN II;

ANIMAL; ARTHRITIS, RHEUMATOID; HUMAN; IMMUNOLOGY; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; MULTIPLE SCLEROSIS; PATHOLOGY;

ANGIOTENSIN II; ANIMALS; ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTIPLE SCLEROSIS;

EID: 84920284695     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12467     Document Type: Review

References (99)

1. Aviña-Zubieta JA, Choi HK, Sadatsafavi M etal. Risk of cardiovascular mortality in patients with RA: a meta-analysis of observational studies. Arthritis Rheum 2008; 59:1690-1697.
2. Meune C, Touzé E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in RA: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis 2010; 103:253-261.
3. Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Wolfe F. Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in RA. J Rheumatol 2007; 34:943-951.
4. Solomon DH, Kremer J, Curtis JR etal. Explaining the cardiovascular risk associated with RA traditional risk factors versus markers of RA severity. Ann Rheum Dis 2010; 69:1920-1925.
5. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008; 121:S21-31.
6. Kremers HM, Crowson CS, Therneau TM, Roger VL, Gabriel SE. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population based cohort study. Arthritis Rheum 2008; 58:2268-2274.
7. Bataller R, Gines P, Nicolas JM etal. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118:1149-1156.
8. Neves SR, Ram PT, Iyengar R. G protein pathways. Science 2002; 296:1636-1639.
9. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 2003; 12:70-88.
10. Stoll M, Unger T. Angiotensin and its AT2 receptor: new insights into an old system. Regul Pept 2001; 99:175-182.
11. Burson JM, Aguilera G, Gross KW, Sigmund CD. Differential expression of angiotensin receptor 1A and 1B in mouse. Am J Physiol 1994; 267:E260-267.
12. Oliverio MI, Coffman TM. Angiotensin II receptor physiology using gene targeting. News Physiol Sci 2000; 15:171-175.
13. Steckelings UM, Kaschina E, Unger T. The AT2 receptor-a matter of love and hate. Peptides 2005; 26:1401-1409.
14. Nataraj C, Oliverio MI, Mannon RB etal. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 1999; 104:1693-1701.
15. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008; 29:367-374.
16. Dagenais NJ, Jamali F. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy 2005; 25:1213-1229.
17. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International Union of Pharmacology: XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52:415-472.
18. Widdop R, Jones E, Hannan R, Gaspari T. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol 2003; 140:809-824.
19. Jones ES, Black MJ, Widdop RE. Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. J Mol Cell Cardiol 2004; 37:1023-1030.
20. Mogi M, Li JM, Iwanami J etal. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 2006; 48:141-148.
21. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995; 25:913-917.
22. Alvarez A, Cerdá-Nicolás M, Naim Abu Nabah Y etal. Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood 2004; 104:402-408.
23. Piqueras L, Kubes P, Alvarez A etal. Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation. Circulation 2000; 102:2118-2123.
24. Nobuhiko A, Suganuma E, Babaev VR etal. Angiotensin II amplifies macrophage-driven atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24:2143-2148.
25. Han C, Liu J, Liu X, Li M. Angiotension II induces C-reactive protein expression through ERK1/2 and JNK signaling in human aortic cells. Atherosclerosis 2010; 212:206-212.
26. Wang CH, Li SH, Weisel RD etal. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107:1783-1790.
27. Dandona P, Kumar V, Aljada A etal. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003; 88:4496-4501.
28. Suzuki Y, Gomez-Guerrero C, Shirato I etal. Susceptibility to T cell-mediated injury in immune complex disease is linked to local activation of rennin-angiotensin system: the role of NF-AT pathway. J Immunol 2002; 169:4136-4146.
29. Muller DN, Shagdarsuren E, Park JK etal. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 2002; 161:1679-1693.
30. Guzik TJ, Hoch NE, Brown KA etal. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204:2449-2460.
31. Friedland J, Setton C, Silverstein E. Angiotensin converting enzyme: induction by steroids in rabbit alveolar macrophages in culture. Science 1977; 197:64-65.
32. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol 2005; 25:2106-2113.
33. Kim MP, Zhou M, Wahl LM. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J Leukoc Biol 2005; 78:195-201.
34. Ruiz-Ortega M, Bustos C, Hernández-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates in mononuclear cell recruitment in the kidney through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 gene expression. J Immunol 1998; 161:430-439.
35. Ortego M, Bustos C, Hernández-Presa MA etal. Atorvastatin reduces NF kappa B activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147:253-261.
36. Jurewicz M, McDermott DH, Sechler JM etal. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 2007; 18:1093-1102.
37. Kossmann S, Schwenk M, Hausding M etal. Angiotensin II-induced vascular dysfunction depends on interferon-γ-driven immune cell recruitment and mutual activation of monocytes and NK-cells. Arterioscler Thromb Vasc Biol 2013; 33:1313-1319.
38. Goldszmid RS, Caspar P, Rivollier A etal. NK cell-derived interferon-γ orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection. Immunity 2012; 36:1047-1059.
39. Welte S, Kuttruff S, Waldhauer I, Steinle A. Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat Immunol 2006; 7:1334-1342.
40. Mateo T, Abu Nabah YN, Abu Taha M etal. Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J Immunol 2006; 176:5577-5586.
41. Nabah YN, Mateo T, Estellés R etal. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 2004; 110:3581-3586.
42. Lapteva N, Ide K, Nieda M etal. Activation and suppression of reninangiotensin system in human dendritic cells. Biochem Biophys Res Commun 2002; 296:194-200.
43. Nahmod K, Gentilini C, Vermeulen M etal. Impaired function of dendritic cells deficient in angiotensin II type 1 receptors. J Pharmacol Exp Ther 2010; 334:854-862.
44. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2010; 2:247-257.
45. Wei-guo Z, Hui Y, Shan L etal. PPAR-gamma agonist inhibits Ang II-induced activation of dendritic cells via the MAPK and NF-kappa B pathways. Immunol Cell Biol 2010; 88:305-312.
46. Nie W, Yan H, Li S etal. Angiotensin-(1-7) enhances angiotensin II induced phosphorylation of ERK1/2 in mouse bone marrow-derived dendritic cells. Mol Immunol 2009; 46:355-361.
47. Odaka C, Mizuochi T. Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals. Clin Exp Immunol 2000; 121:515-522.
48. Coelho dos Santos JS, Menezes CA, Villani FN etal. Captopril increases the intensity of monocyte infection by Trypanosoma cruzi and induces human T helper type 17 cells. Clin Exp Immunol 2010; 162:528-536.
49. Kvakan H, Kleinewietfeld M, Qadri F etal. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 2009; 119:2904-2912.
50. Hoch NE, Guzik TJ, Chen W etal. Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol 2009; 296:R208-216.
51. Shao J, Nangaku M, Miyata T etal. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 2003; 42:31-38.
52. -/- mice. Hypertension 2004; 44:277-282.
53. Sagawa K, Nagatani K, Komagata Y, Yamamoto K. Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice. Arthritis Rheum 2005; 52:1920-1928.
54. Akdis CA, Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 2009; 123:735-746.
55. Zhang JD, Patel MB, Song YS etal. A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ Res 2012; 110:1604-1617.
56. Barhoumi T, Kasal DA, Li MW etal. T Regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 2011; 57:469-476.
57. Agha AM, Mansour M. Effects of captopril on interleukin-6, leukotriene B(4), and oxidative stress markers in serum and inflammatory exudate of arthritic rats: evidence of anti-inflammatory activity. Toxicol Appl Pharmacol 2000; 168:123-130.
58. Caspritz G, Alpermann HG, Schleyerbach R. Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat. Arzneimittelforschung 1986; 36:1605-1608.
59. Dalbeth N, Edwards J, Fairchild S, Callan M, Hall FC. The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Rheumatology (Oxf) 2005; 44:24-31.
60. Sakuta T, Morita Y, Satoh M, Fox DA, Kashihara N. Involvement of the rennin-angiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers. Arthritis Rheum 2010; 62:1319-1328.
61. Silveira KD, Coelho FM, Vieira AT etal. Mechanisms of the anti-inflammatory actions of the angiotensin type 1 receptor antagonist losartan in experimental models of arthritis. Peptides 2013; 46:53-63.
62. Mackenzie A, Dunning L, Ferrell WR, Lockhart JC. Angiotensin II Type 1 receptor blockade protects endothelium-derived hyperpolarising factor-mediated relaxation in a rat model of monoarthritis. Life Sci 2013; 92:1131-1137.
63. Dessein PH, Solomon A, Woodiwiss AJ, Norton GR, Tsang L, Gonzalez-Gay MA. Marked independent relationships between circulating interleukin-6 concentrations and endothelial activation in rheumatoid arthritis. Mediators Inflamm 2013; 2013:1-10.
64. Södergren A, Karp K, Boman K etal. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 2010; 12:R158.
65. Refaat R, Salama M, Abdel Meguid E, El Sarha A, Gowayed M. Evaluation of the effect of losartan and methotrexate combined therapy in adjuvant-induced arthritis in rats. Eur J Pharmacol 2013; 698:421-428.
66. Wang D, Hu S, Zhu J etal. Angiotensin II type 2 receptor correlates with therapeutic effects of losartan in rats with adjuvant-induced arthritis. J Cell Mol Med 2013; 17:1577-1587.
67. Walsh DA, Suzuki T, Knock GA, Blake DR, Polak JM, Wharton J. AT1 receptor characteristics of angiotensin analogue binding in human synovium. Br J Pharmacol 1994; 112:435-442.
68. Price A, Lockhart JC, Ferrell WR, Gsell W, McLean S, Sturrock RD. Angiotensin II type 1 receptor as a novel therapeutic target in rheumatoid arthritis: in vivo analyses in rodent models of arthritis and ex vivo analyses in human inflammatory synovitis. Arthritis Rheum 2007; 56:441-447.
69. Kawakami Y, Matsuo K, Murata M etal. Expression of angiotensin II receptor-1 in human articular chondrocytes. Arthritis 2012; 2012:1-7.
70. Goto M, Fujisawa M, Yamada A etal. Spontaneous release of angiotensin converting enzyme and interleukin 1 beta from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition. Ann Rheum Dis 1990; 49:172-176.
71. Goto M, Sasano M, Fuzisawa M, Okabe T, Nishizawa K. Constitutive production of angiotensin converting enzyme from rheumatoid nodule cells under serum free conditions. Ann Rheum Dis 1992; 51:741-742.
72. Veale D, Yanni G, Bresnihan B, FitzGerald O. Production of angiotensin converting enzyme by rheumatoid synovial membrane. Ann Rheum Dis 1992; 51:476-480.
73. Walsh DA, Catravas J, Wharton J. Angiotensin converting enzyme in human synovium: increased stromal [(125)I]351A binding in rheumatoid arthritis. Ann Rheum Dis 2000; 59:125-131.
74. Fukuzawa M, Satoh J, Sagara M etal. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology 1997; 36:49-55.
75. Martin MF, Surrall KE, McKenna F, Dixon JS, Bird HA, Wright V. Captopril: a new treatment for rheumatoid arthritis? Lancet 1984; 1:1325-1328.
76. Bird HA, Le Gallez P, Dixon JS etal. A clinical and biochemical assessment of a nonthiol ACE inhibitor (pentopril; CGS-13945) in active rheumatoid arthritis. J Rheumatol 1990; 17:603-608.
77. Flammer AJ, Sudano I, Hermann F etal. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 2008; 117:2262-2269.
78. Perry ME, Chee MM, Ferrell WR, Lockhart JC, Sturrock RD. Angiotensin receptor blockers reduce erythrocyte sedimentation rate levels in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67:1646-1647.
79. van Halm VP, Peters MJ, Voskuyl AE etal. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009; 68:1395-1400.
80. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369:1208-1219.
81. Peng JF, Gurantz D, Tran V, Cowling RT, Greenberg BH. Tumor necrosis factor-α-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis. Circ Res 2002; 91:1119-1126.
82. Wassman S, Stumpf M, Stehlow K etal. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 2004; 94:534-541.
83. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35:881-900.
84. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903-911.
85. Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernán MA etal. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108:1362-1370.
86. Peters MJ, van Sijl AM, Voskuyl AE, Sattar N, Smulders YM etal. The effects of tumor necrosis factor inhibitors on cardiovascular risk in RA. Curr Pharm Des 2012; 18:1502-1511.
87. Mäki-Petäjä KM, Hall FC, Booth AD, Wallace SM, Yasmin, Bearcroft PW etal. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006; 114:1185-1192.
88. van Vollenhoven RF, Emery P, Bingham CO 3rd etal. Long-term safety of rituximab in rheumatoid arthritis: 9 5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013; 72:1496-1502.
89. Kawashiri SY, Kawakami A, Yamasaki S etal. Effects of the antiinterleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 2011; 31:451-456.
90. Fleischmann R, Kremer J, Cush J etal. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367:495-507.
91. Montecucco F, Mach F. Statins, ACE inhibitors and ARBs in cardiovascular disease. Best Pract Res Clin Endocrinol Metab 2009; 23:389-400.
92. Protogerou AD, Panagiotakos DB, Zampeli E etal. Arterial hypertension assessed 'out-of-office' in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated 'white coat' phenomenon. Arthritis Res Ther 2013; 15:R142.
93. Peters MJ, Symmons DP, McCarey D etal. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69:325-331.
94. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355:637-645.
95. Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitors. Ann Pharmacother 1996; 30:55-61.
96. Resende MM, Mill JG. Alternate angiotensin II-forming pathways and their importance in physiological or physiopathological conditions. Arq Bras Cardiol 2002; 78:425-438.
97. Carey RM, Howell NL, Jin XH, Siragy HM. Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptor-blocked rats. Hypertension 2001; 38:1272-1277.
98. Widdop RE, Matrougui K, Levy BI, Henrion D. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension 2002; 40:516-520.
99. McCarey DW, McInnes IB, Madhok R etal. Trial of Atorvastatin in rheumatoid arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 2004; 363:2015-2021.